These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6796187)

  • 41. Prostaglandin E1 in severe Raynaud's phenomenon.
    Pardy BJ; Hoare MC; Eastcott HH; Miles CC; Needham TN; Harbourne T; Ellis BW
    Surgery; 1982 Dec; 92(6):953-65. PubMed ID: 6890719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 44. Raynaud's disease and prostacyclin.
    Kennerly D
    Ann Intern Med; 1983 Feb; 98(2):258. PubMed ID: 6337542
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 46. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of PG E2 and PG I2 on the adenylate cyclase activity in rat intestinal epithelial cells.
    Simon B; Seitz H; Kather H
    Biochem Pharmacol; 1980 Feb; 29(4):673-5. PubMed ID: 6989371
    [No Abstract]   [Full Text] [Related]  

  • 48. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P
    Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252
    [No Abstract]   [Full Text] [Related]  

  • 49. The treatment of Raynaud's phenomenon.
    Dowd PM
    Br J Dermatol; 1986 May; 114(5):527-33. PubMed ID: 2872912
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2 and I2.
    Crutchley DJ; Conanan LB; Maynard JR
    J Pharmacol Exp Ther; 1982 Sep; 222(3):544-9. PubMed ID: 7050342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distinction between prostaglandin E2 and prostacyclin as inhibitors of granulmoatous inflammation.
    Parnham MJ; Bonta IL; Adolfs MJ
    J Pharm Pharmacol; 1979 Aug; 31(8):565-7. PubMed ID: 40005
    [No Abstract]   [Full Text] [Related]  

  • 53. [Analogs of prostaglandin-related substances and inhibitors of their formation and metabolism. Clinical application to the surgical field].
    Mishima Y
    Nihon Rinsho; 1985 Mar; 43(3):598-602. PubMed ID: 3892091
    [No Abstract]   [Full Text] [Related]  

  • 54. Platelet preservation during cardiopulmonary bypass (CPB) with prostaglandin (PGE1) and prostacyclin (PGI2).
    van den Dungen JJ; Velders AJ; Karliczek GF; Homan van der Heide JN; Wildevuur CR
    Trans Am Soc Artif Intern Organs; 1980; 26():481-6. PubMed ID: 7018057
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
    Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD
    Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038
    [No Abstract]   [Full Text] [Related]  

  • 56. Histologic and hemodynamic effects of prostacyclin and prostaglandin E1 following oleic acid infusion.
    Slotman GJ; Machiedo GW; Casey KF; Lyons MJ
    Surgery; 1982 Jul; 92(1):93-9. PubMed ID: 7046123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostaglandin-related renin release from rabbit renal cortical slices.
    Spokas EG; Wong PY; McGiff JC
    Hypertension; 1982; 4(3 Pt 2):96-100. PubMed ID: 7040243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of prostaglandin E1 and polyphloretin phosphate on hemolysis of human erythrocytes.
    Taniguchi M; Aikawa M; Sakagami T
    J Biochem; 1982 Apr; 91(4):1173-9. PubMed ID: 7201469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Action of prostacyclin (PGI2) and prostaglandin E2 (PGE2) on gastric secretion and mucosal blood flow in dogs.
    Konturek SJ
    Gastroenterology; 1980 Jul; 79(1):182-4. PubMed ID: 6991360
    [No Abstract]   [Full Text] [Related]  

  • 60. Interactions between prostaglandin E2 and prostacyclin in regulating levels of cyclic AMP in elicited populations of peritoneal macrophages.
    Bonta IL; Adolfs MJ
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():13-7. PubMed ID: 6303080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.